3 recruiting. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 3 | 3 | Recruiting 3 |
Follow Malignancy: new trials by email Literature Review of Malignancy trials Research Report on Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Atezolizumab - Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-10-25 | 2025-11-24 |
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Glioma (2) · Hematologic Neoplasms (2) · Lymphoproliferative Disorders (2) · Melanoma (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Neuroblastoma (1) · Sarcoma (1) · Stomach Neoplasms (1)
Hemic and Lymphatic Diseases (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3) · Neuroectodermal Tumors (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Hematologic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Neuroepithelial (2) · Neuroendocrine Tumors (2)
atezolizumab (1) · capmatinib (1) · entrectinib (1)
United Kingdom (3)